Librería Servicio Médico

Author : Stefan Dübel / Janice M. Reichert 

Language: English

Finishing : Hardcover, 2544 pages

ISBN : 978-3-527-32937-3

Edition Number: 2014

Description:

Still the most comprehensive reference source on the development, production and therapeutic application of antibodies, this second edition is thoroughly updated and now has 30% more content. 

Volume 1 covers selection and engineering strategies for new antibodies, while the second volume presents novel therapeutic concepts and antibodies in clinical study, as well as their potential. Volumes 3 and 4 feature detailed and specific information about each antibody approved for therapeutic purposes, including clinical data. This unique handbook concludes with a compendium of marketed monoclonal antibodies and an extensive index.

Beyond providing current knowledge, the authors discuss emerging technologies, future developments, and intellectual property issues, such that this handbook meets the needs of academic researchers, decision makers in industry and healthcare professionals in the clinic.

Author Information:

Stefan Dübel received his Ph.D. at the Center for Molecular Biology in Heidelberg, Germany, before moving on to the German Cancer Research Center in 1989 where he started research on the development of antibody libraries with naive or synthetic CDRs. In the following years, he substantially participated in the invention of antibody phage display, as well as other recombinant antibody technologies and the development of various antibody fusion proteins. In 1996, he moved to the University of Heidelberg to establish the antibody engineering group at the Institute of Molecular Genetics. He was appointed full professor at the Technische Universität Braunschweig in 2002, where he currently is head of the Department of Biotechnology and managing director of the Institute of Biochemistry, Biotechnology and Bioinformatics. He has co-authored more than 100 original papers, many patents, as well as several acknowledged textbooks in the field of recombinant antibodies. He is also on the editorial board of several scientific journals and cofounder of two antibody engineering companies. 

Janice M. Reichert is an internationally recognized expert in the development of antibody therapeutics. She is Founder and Managing Director of Reichert Biotechnology Consulting LLC, a pharmaceutical business intelligence research firm, and the founding Editor-in-Chief of "mAbs", a peer-reviewed, PubMed-indexed biomedical journal that focuses on topics relevant to antibody research and development. Dr. Reichert has published extensively on development trends for antibody therapeutics and she has presented her research results as an invited speaker at conferences held worldwide. She is President of The Antibody Society and serves on the editorial boards of several biomedical journals. Dr. Reichert received her Ph.D. from the University of Pennsylvania and her post-doctoral training at Harvard Medical School.

Table Of Contents:

• Technologies
• Foreword : Glassy
• A Greeting from the Editor: Dübel
• Introduction: Therapeutic Antibodies - From Past to Future Dübel

Part I: Selecting and Shaping the Antibody Molecule

• Selection strategies I: Monoclonal Antibodies Moldenhauer
• Selection strategies II: Phage Antibody Display Hust
• Selection strategies III: Transgenic Mice Brüggemann
• Bioinformatic Tools for Antibody Engineering Martin
• Molecular Engineering I: Humanization Saldanha (X)
• Molecular Engineering II: Affinity Maturation Roskos
• Molecular Engineering III: Fc Engineering Valerius

Part II: Preparing The Way into the Clinic

• Production and Downstream Processing Bergemann
• Pharmaceutical Formulation and Clinical Application Reich
• Immunogenicity of Antibody Therapeutics Schellekens
• Glycoanalytics Beck (new)

Part III: Beyond IgG: Modified Antibodies

• Immunoscintigraphy and Radioimmunotherapy Dearling
• Bispecific Antibodies Kontermann
• Immunotoxins /
• Targeted RNases Rybak

Part IV: Emerging Concepts

• Automation of Selection and Engineering Konthur
• Emerging Technologies for Antibody Selection Taussig
• Emerging Alternative Production Systems Jostock
• Non-Antibody Scaffolds Skerra
• Emerging Therapeutic Concepts I: ADEPT Sharma
• Emerging Therapeutic Concepts II: Nanotechnology Dimitrov
• Emerging Therapeutic Concepts III:Cell-bound antibodies Schirrmann
• Emerging Therapeutic Concepts IV:Anti-idiotypic Antibodies Fischer
• Recombinant Antibodies for target reserach Dübel (new)
• Therapeutics

Part V: IP and regulatory issues

• Antibody engineering Patents Braunagel
• Quality standards of clinical studies Begent (new)
• Regulatory issues of approving antibody therapeutics Shapiro (FDA)

Part VI: Ongoing Clinical Studies:

• Antibodies in Phase I/II/III: Cancer Therapy Deckert
• Antibodies in Phase I/II/III: Infectious Diseases N.N. (new)
• Antibodies in Phase I/II/III: Targeting TNF Neurath

Part VII: Impact of Biosimilars of mAbs to innovative molecules N.N.

• IP expiration landscape and Biosimilar pathways N.N.
• High mAb Titer of Mammalian Cell Culture N.N.
• Advanced DSP for mAb Production N.N.
• Future mAb Manufacturing Facility: Flexibility and Feasible Sizes N.N.

Part VIII: Approved Antibodies

• Serum Products Behrens (new)
• Adalimumab (Humira) Kupper
• Alemtuzumab (Mabcampath) Elter
• Bevacizumab (Avastin) Díaz-Rubio
• Cetuximab (Erbitux) Schleucher
• Efalizumab (Raptiva) Jahn/Schmitt
• Fanolesomab/Technetium99m (Neutrospec) Palestro
• Gemtuzumab Ozogamicin (Mylotarg) Gramatzki/Peipp
• Infliximab (Remicade) Antoni
• Muromonab (Orthoclone) Becker
• Natalizumab (Tysabri) Gold/Schimrigk
• Omalizumab (Xolair) Kroegel
• Palivizumab (Synagis) Schmidt AC
• Rituximab (Rituxan) Wenger
• Trastuzumab (Herceptin) Ellis
• Plus 8-10 articles on new technologies and additional antibodies approved after print of first edition.
• N.N. (new)

Valoración:

¡Sea el primero en dejar un comentario!

Nuevo Comentario